Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
作者信息
Wermke Martin, Kraus Sabrina, Ehninger Armin, Bargou Ralf C, Goebeler Maria-Elisabeth, Middeke Jan Moritz, Kreissig Carla, von Bonin Malte, Koedam Jan, Pehl Michael, Bornhäuser Martin, Einsele Hermann, Ehninger Gerhard, Cartellieri Marc
机构信息
Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
National Center for Tumor Diseases, Dresden, Germany.
出版信息
Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759.
Abstract
摘要
相似文献
1
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.具有UniCAR-T-CD123的快速可切换通用CAR-T平台用于复发/难治性急性髓系白血病的概念验证
Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759.
2
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.评价针对 CD123 阳性 AML 的通用嵌合抗原受体 T 细胞（UniCAR）中转导的开关共刺激对成本的影响。
Oncoimmunology. 2021 Jul 8;10(1):1945804. doi: 10.1080/2162402X.2021.1945804. eCollection 2021.
3
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.针对急性髓系白血病的FLT3导向的通用型嵌合抗原受体T细胞疗法。
Br J Haematol. 2023 Sep;202(6):1137-1150. doi: 10.1111/bjh.18971. Epub 2023 Jul 17.
4
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.用于治疗CD123阳性白血病的快速可切换通用嵌合抗原受体T细胞
Mol Ther Oncolytics. 2020 Apr 29;17:408-420. doi: 10.1016/j.omto.2020.04.009. eCollection 2020 Jun 26.
5
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.开启和关闭嵌合抗原受体T细胞：一种将T细胞重新靶向急性髓系白血病母细胞的新型模块化平台。
Blood Cancer J. 2016 Aug 12;6(8):e458. doi: 10.1038/bcj.2016.61.
6
How close are we to CAR T-cell therapy for AML?我们距离 CAR T 细胞疗法治疗 AML 还有多远？
Best Pract Res Clin Haematol. 2019 Dec;32(4):101104. doi: 10.1016/j.beha.2019.101104. Epub 2019 Oct 18.
7
Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.嵌合抗原受体（CAR）-NK-92 细胞靶向 CD123 可提高急性髓系白血病的疗效。
Viruses. 2021 Jul 14;13(7):1365. doi: 10.3390/v13071365.
8
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.异体 CD123 CAR-Delta One T（DOT）细胞在急性髓细胞白血病中的生成和概念验证。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005400.
9
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.地西他滨介导的表观遗传重编程增强了针对 CD123 的嵌合抗原受体 T 细胞的抗白血病疗效。
Front Immunol. 2020 Aug 18;11:1787. doi: 10.3389/fimmu.2020.01787. eCollection 2020.
10
[Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].[嵌合抗原受体T细胞疗法治疗急性髓系白血病的现状与未来展望]
Rinsho Ketsueki. 2022;63(10):1446-1453. doi: 10.11406/rinketsu.63.1446.
引用本文的文献
1
The bispecific innate cell engager AFM28 eliminates CD123 leukemic stem and progenitor cells in AML and MDS.双特异性天然细胞衔接器AFM28可清除急性髓系白血病和骨髓增生异常综合征中的CD123白血病干细胞和祖细胞。
Nat Commun. 2025 Aug 21;16(1):7793. doi: 10.1038/s41467-025-63069-y.
2
[Advances in the application strategies of CRISPR/Cas9 technology in chimeric antigen receptor T cell therapy for hematological malignancies].[CRISPR/Cas9技术在血液系统恶性肿瘤嵌合抗原受体T细胞治疗中的应用策略进展]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):481-488. doi: 10.3760/cma.j.cn121090-20240911-00343.
3
CAR-T cell therapy for cancer: current challenges and future directions.用于癌症治疗的嵌合抗原受体T细胞疗法：当前挑战与未来方向
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
4
CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?嵌合抗原受体T细胞疗法治疗急性髓系白血病：我们目前的进展如何？
Curr Oncol. 2025 May 30;32(6):322. doi: 10.3390/curroncol32060322.
5
CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.CliniMACS Prodigy可切换“与”门嵌合抗原受体T细胞的制造。
Int J Mol Sci. 2025 May 23;26(11):5024. doi: 10.3390/ijms26115024.
6
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.下一代免疫疗法设计与工具的见解：分子机制与治疗前景。
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
7
T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.靶向组织蛋白酶G信号肽的T细胞受体模拟嵌合抗原受体T细胞
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02652-0.
8
Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended-Gate Field-Effect-Transistor Biosensors.利用多重扩展栅场效应晶体管生物传感器实现个性化免疫治疗药物监测
Small Sci. 2025 Feb 3;5(5):2400515. doi: 10.1002/smsc.202400515. eCollection 2025 May.
9
Tolerogenic Therapies in Cardiac Transplantation.心脏移植中的耐受性疗法
Int J Mol Sci. 2025 Apr 23;26(9):3968. doi: 10.3390/ijms26093968.
10
CAR T-cells for acute leukemias in children: current status, challenges, and future directions.用于儿童急性白血病的嵌合抗原受体T细胞：现状、挑战及未来方向
Cancer Metastasis Rev. 2025 Apr 23;44(2):47. doi: 10.1007/s10555-025-10261-7.
本文引用的文献
1
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.美国血液学会2020年老年初诊急性髓系白血病治疗指南。
Blood Adv. 2020 Aug 11;4(15):3528-3549. doi: 10.1182/bloodadvances.2020001920.
2
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.基于 41BB 和 CD28 的 CD123 导向 T 细胞在体内消除人正常造血。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000845.
3
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.用于治疗CD123阳性白血病的快速可切换通用嵌合抗原受体T细胞
Mol Ther Oncolytics. 2020 Apr 29;17:408-420. doi: 10.1016/j.omto.2020.04.009. eCollection 2020 Jun 26.
4
How close are we to CAR T-cell therapy for AML?我们距离 CAR T 细胞疗法治疗 AML 还有多远？
Best Pract Res Clin Haematol. 2019 Dec;32(4):101104. doi: 10.1016/j.beha.2019.101104. Epub 2019 Oct 18.
5
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.一种用于PET成像以及重定向表达通用嵌合抗原受体UniCAR的T细胞的诊疗一体化PSMA配体。
Oncoimmunology. 2019 Sep 7;8(11):1659095. doi: 10.1080/2162402X.2019.1659095. eCollection 2019.
6
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?嵌合抗原受体T细胞疗法治疗急性髓系白血病：离现实有多近？
Haematologica. 2019 Jul;104(7):1302-1308. doi: 10.3324/haematol.2018.208751. Epub 2019 Jun 20.
7
The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.UniCAR 系统：一种模块化 CAR T 细胞方法，旨在提高 CAR T 细胞的安全性。
Immunol Lett. 2019 Jul;211:13-22. doi: 10.1016/j.imlet.2019.05.003. Epub 2019 May 12.
8
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
9
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
10
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.细胞因子释放综合征和神经毒性的新见解：CD19 特异性嵌合抗原受体 T 细胞治疗后。
Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3.
Zotero 插件